The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen ...

Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer ...

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...

Life Line Prostate Cancer Screening Program offers comprehensive PSA testing for men 50+ through over 14,000 convenient locations nationwide. With packages starting at $159 and specialized men's ...

Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

Combination treatments are improving survival rates in prostate cancer, but expanding access to innovative care is a vital piece of the puzzle. Prostate cancer is the most common non-skin cancer in ...

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...

California has seven hospitals on Healthgrades’ list of America’s 50 Best Hospitals for Outpatient Prostate Care, the most of ...

A systematic review of 88 studies covering 29,256 people with prostate cancer maps preferences for digital supportive care, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...